Download
fphar-11-01258.pdf 1,32MB
WeightNameValue
1000 Titel
  • Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
1000 Autor/in
  1. Saha, Rudra P. |
  2. Sharma, Ashish Ranjan |
  3. Singh, Manoj K. |
  4. Samanta, Saikat |
  5. Bhakta, Swarnav |
  6. Mandal, Snehasish |
  7. Bhattacharya, Manojit |
  8. Lee, Sang-Soo |
  9. Chakraborty, Chiranjib |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-08-19
1000 Erschienen in
1000 Quellenangabe
  • 11:1258
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fphar.2020.01258 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466451/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • As the COVID-19 is still growing throughout the globe, a thorough investigation into the specific immunopathology of SARS-CoV-2, its interaction with the host immune system and pathogen evasion mechanism may provide a clear picture of how the pathogen can breach the host immune defenses in elderly patients and patients with comorbid conditions. Such studies will also reveal the underlying mechanism of how children and young patients can withstand the disease better. The study of the immune defense mechanisms and the prolonged immune memory from patients population with convalescent plasma may help in designing a suitable vaccine candidate not only for the current outbreak but also for similar outbreaks in the future. The vital drug candidates, which are being tested as potential vaccines or therapeutics against COVID-19, include live attenuated vaccine, inactivated or killed vaccine, subunit vaccine, antibodies, interferon treatment, repurposing existing drugs, and nucleic acid-based vaccines. Several organizations around the world have fast-tracked the development of a COVID-19 vaccine, and some drugs already went to phase III of clinical trials. Hence, here, we have tried to take a quick glimpse of the development stages of vaccines or therapeutic approaches to treat this deadly disease.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal vaccine development
lokal repurposed drug
lokal coronavirus
lokal SARS-CoV-2
lokal antiviral treatment
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U2FoYSwgUnVkcmEgUC4=|https://frl.publisso.de/adhoc/uri/U2hhcm1hLCBBc2hpc2ggUmFuamFu|https://frl.publisso.de/adhoc/uri/U2luZ2gsIE1hbm9qIEsu|https://frl.publisso.de/adhoc/uri/U2FtYW50YSwgU2Fpa2F0|https://frl.publisso.de/adhoc/uri/Qmhha3RhLCBTd2FybmF2|https://frl.publisso.de/adhoc/uri/TWFuZGFsLCBTbmVoYXNpc2g=|https://frl.publisso.de/adhoc/uri/QmhhdHRhY2hhcnlhLCBNYW5vaml0|https://frl.publisso.de/adhoc/uri/TGVlLCBTYW5nLVNvbw==|https://frl.publisso.de/adhoc/uri/Q2hha3JhYm9ydHksIENoaXJhbmppYg==
1000 Label
1000 Förderer
  1. Hallym University |
  2. National Research Foundation of Korea |
  3. Ministry of Education |
1000 Fördernummer
  1. -
  2. NRF-2017R1A2B4012944; NRF-2020R1C1C1008694
  3. -
1000 Förderprogramm
  1. Research Fund
  2. Basic Science Research Program
  3. Basic Science Research Program
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Hallym University |
    1000 Förderprogramm Research Fund
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer National Research Foundation of Korea |
    1000 Förderprogramm Basic Science Research Program
    1000 Fördernummer NRF-2017R1A2B4012944; NRF-2020R1C1C1008694
  3. 1000 joinedFunding-child
    1000 Förderer Ministry of Education |
    1000 Förderprogramm Basic Science Research Program
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6428104.rdf
1000 Erstellt am 2021-06-09T11:18:34.009+0200
1000 Erstellt von 218
1000 beschreibt frl:6428104
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet 2021-07-01T12:25:15.418+0200
1000 Objekt bearb. Thu Jul 01 12:25:15 CEST 2021
1000 Vgl. frl:6428104
1000 Oai Id
  1. oai:frl.publisso.de:frl:6428104 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source